Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

milrebrutinib

An orally bioavailable, non-covalent inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, milrebrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a drug resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK or the C481S mutated form. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B lymphocytes.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Bruton's tyrosine kinase inhibitor AS-1763
BTK inhibitor AS-1763
Code name:AS 1763
AS-1763
AS1763
BN 102
BN-102
BN102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search